The current financial score of CAMP4 Therapeutics Corp is 6.04. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 1.78M, representing a year-over-year increase of 18.84%, while its net profit experienced a year-over-year increase of 166.39%.
The current valuation score of CAMP4 Therapeutics Corp is 8.62. Its current P/E ratio is -1.59, which is -67.42% below the recent high of -0.52 and -180.41% above the recent low of -4.45.
The current earnings forecast score of CAMP4 Therapeutics Corp is 8.86. The average price target is 10.10, with a high of 15.00 and a low of 6.50.
The current price momentum score of CAMP4 Therapeutics Corp is 3.99. Currently, the stock price is trading between the resistance level at 4.36 and the support level at 3.37, making it suitable for range-bound swing trading.
The current institutional shareholding score of CAMP4 Therapeutics Corp is 7.00. The latest institutional shareholding proportion is 82.01%, representing a quarter-over-quarter increase of 237.71%.
The current risk assessment score of CAMP4 Therapeutics Corp is 2.34. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.